Combination Therapy for Initially Unresectable Liver Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of liver procedures (TACE or HAIC) with anti-angiogenic drugs and immunotherapy to shrink liver cancer that cannot be removed with surgery. If the tumor shrinks enough, you may be able to have surgery or continue with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed with surgery.
- You have not had any systemic treatment (like pills or IV therapy) for your liver cancer before.
- Your liver function is good enough (Child-Pugh A or B) and you are able to do daily activities (ECOG 0-1).
- You are willing to have a treatment that combines a liver procedure (TACE or HAIC) with anti-angiogenic drugs and immunotherapy.
- After the initial treatment, you may be able to have surgery to remove the cancer or continue with other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This trial tests a combination of three treatments—a targeted artery procedure, a growth-blocking drug (apatinib), and an immune-boosting drug (camrelizumab)—for people with advanced liver cancer who cannot or do not want surgery. The goal is to shrink tumors and improve survival.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Hear when a new Unresectable Hepatocellular Carcinom trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.